Orion and Criceto Collaborate on APORON® for Parkinson’s Disease
Orion Corporation and Criceto IKM B.V. have come together to form a groundbreaking partnership aimed at the development and commercialization of APORON®, a novel apomorphine oromucosal spray. This medication is designed specifically for treating OFF episodes in patients suffering from Parkinson’s disease, a condition characterized by disabling motor fluctuations. Currently, APORON® finds itself in the critical Phase 3 development stage led by Criceto.
Understanding the License Agreement
The mutual agreement grants Orion an exclusive license to distribute Criceto’s proprietary apomorphine spray in various global markets, excluding only the United States and Canada. Patients dealing with OFF episodes often experience significant challenges that adversely affect their quality of life, making effective treatment essential.
The Importance of the Treatment
APORON® serves as a rescue therapy, offering on-the-spot relief for patients experiencing such episodes. The agreement between the companies includes provisions for upfront payments, cost reimbursements for ongoing development, and future royalties—establishing a solid financial framework for the collaboration.
A Commitment to Patient Care
Hao Pan, Executive Vice President of Branded Products at Orion, expressed enthusiasm about this venture, stating, "We are excited to enter this collaboration with Criceto. At Orion, we strive to improve the lives of patients living with Parkinson’s disease, aiming to provide treatment options for all stages and assist patients during their journey.”
Enhancing Parkinson’s Disease Management
Dr. Bert Tuk, Chief Executive Officer of Criceto, also highlighted the importance of the partnership: “This collaboration leverages Criceto’s expertise in developing advanced rescue treatments for Parkinson’s disease. We are proud to advance the APORON® project, which has the potential to be the leading rescue treatment for OFF episodes.”
About Criceto IKM B.V.
Criceto is an innovative, privately held pharmaceutical company dedicated to enhancing care for patients suffering from Parkinson’s disease. Their focus is specifically on creating and advancing treatment solutions like APORON®, which is currently making significant strides in its development, aiming to become the first choice for managing OFF episodes in patients.
About Orion Corporation
Orion has been a cornerstone in the pharmaceutical industry for over a century, providing well-being-driven solutions. This Nordic company excels in the development and marketing of both human and veterinary pharmaceuticals, alongside a varied portfolio that includes consumer health products. Orion’s R&D is robust, focusing on oncology and pain management, among other critical areas. Recently, Orion reported net sales reaching EUR 1,542 million, supporting a dedicated team of around 3,700 professionals committed to patient health. Their shares are traded on Nasdaq Helsinki under the ticker ORNBV.
Contact Information for Inquiries
For further information, you can reach out to:
Hao Pan
Executive Vice President, Branded Products
Tel: +44 16 3552 0300
Frequently Asked Questions
What is APORON®?
APORON® is an innovative apomorphine spray designed to provide treatment for OFF episodes in Parkinson’s disease patients.
What does the license agreement entail?
The license agreement allows Orion to exclusively market Criceto’s apomorphine spray globally, excluding the US and Canada.
What is the significance of the partnership?
This collaboration enhances treatment options for patients and aims to make a notable impact on the management of Parkinson’s disease.
Who can benefit from APORON®?
Patients experiencing OFF episodes associated with Parkinson’s disease can benefit from this new treatment option.
How is Orion involved in the pharmaceutical industry?
Orion is a longstanding pharmaceutical company developing a wide range of human and veterinary drugs, focusing on patient well-being for over a hundred years.
